BiomX Ltd. Files for Insolvency After Halting Phase 2b Study
I'm PortAI, I can summarize articles.
BiomX Ltd., an Israeli subsidiary of BiomX Inc., has filed for insolvency following the halt of its Phase 2b study due to limited financial resources. The parent company is exploring strategic options and retains ownership of its BX011 program for diabetic foot infections, managed by Adaptive Phage Therapeutics, Inc. This information was originally published by BiomX Inc. via the U.S. SEC's EDGAR system.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments